MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro cell culture and in vivo mouse xenograft study
PubMed 20962322 · doi:10.1182/blood-2009-11-253294
What was done
Researchers evaluated the functional role of the microRNA-15a/16-1 cluster (located at the 13q14 deletion region) in multiple myeloma pathogenesis. They used lentiviral sponge vectors to competitively and stably inhibit mature microRNAs in vitro and in vivo in a mouse xenograft model. Downstream targets and gene expression alterations following miR-16 inhibition were assessed using expression profiling and target validation assays.
What was found
Stable inhibition of miR-16 enhanced the proliferative and invasive capacity of multiple myeloma cells. In xenograft animal models, miR-16 inhibition increased tumor load and host angiogenesis, resulting in decreased survival. Expression profiling identified direct targets of miR-16, including FGFR1, PI3KCa, MDM4, and VEGFa (with binding sites in both the conserved 3'-UTR and mRNA coding regions), as well as secondary downstream genes such as JUN and Jag1. The abstract reported no quantitative effect sizes, survival figures, or statistical intervals.
Why it matters
The findings characterize the miR-15a/16-1 cluster as functional tumor suppressors in multiple myeloma, mechanistically linking the common 13q14 chromosomal deletion to oncogenic signaling, angiogenesis, and tumor growth.
Limits
The study is restricted to preclinical in vitro assays and mouse xenograft models, which cannot establish clinical efficacy or human patient outcomes. Sample sizes, quantitative metrics, and variance data are omitted from the abstract. Additionally, this publication has been formally retracted.
Cited by
- context A multiple myeloma study from the Dana-Farber Cancer Institute published in Blood contained duplicated/manipulated images where day 1 control group images were reused for day 16 intervention groups to claim tumor suppression.